jansucko / iStockphoto.com
28 September 2018
CRISPR specialist raises $80m in funding
US company KSQ Therapeutics, a specialist in using CRISPR for drug development, has raised $80 million in series C funding.
Already registered?
Login to your account
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
Americas
20 March 2017 Allergan Pharmaceuticals and genome-editing company Editas Medicine have entered into a strategic research and development agreement over CRISPR technology.
Europe
29 October 2015 Philip Webber, partner at Dehns Patent & Trademark Attorneys, looks at the clarity of the language used in the Broad Institute of MIT and Harvard’s granted European patents for the CRISPR technology and questions whether it satisfies the European Patent Office’s requirements.
Biotechnology
23 November 2018 The global CRISPR technology market is expected to reach $1.72 million in value by 2023, up from 2018’s predicted figure of $562 million, according to a report released this month.
Editor's picks
Editor's picks
Americas
20 March 2017 Allergan Pharmaceuticals and genome-editing company Editas Medicine have entered into a strategic research and development agreement over CRISPR technology.
Biotechnology
23 November 2018 The global CRISPR technology market is expected to reach $1.72 million in value by 2023, up from 2018’s predicted figure of $562 million, according to a report released this month.
Europe
29 October 2015 Philip Webber, partner at Dehns Patent & Trademark Attorneys, looks at the clarity of the language used in the Broad Institute of MIT and Harvard’s granted European patents for the CRISPR technology and questions whether it satisfies the European Patent Office’s requirements.
Americas
20 March 2017 Allergan Pharmaceuticals and genome-editing company Editas Medicine have entered into a strategic research and development agreement over CRISPR technology.
Biotechnology
23 November 2018 The global CRISPR technology market is expected to reach $1.72 million in value by 2023, up from 2018’s predicted figure of $562 million, according to a report released this month.
Europe
29 October 2015 Philip Webber, partner at Dehns Patent & Trademark Attorneys, looks at the clarity of the language used in the Broad Institute of MIT and Harvard’s granted European patents for the CRISPR technology and questions whether it satisfies the European Patent Office’s requirements.